##### Dr Jennifer S Lees

*MA (Cantab) MBChB MRCP (Neph) PhD FERA*

*Curriculum Vitae*

**Current positions**

* 2024-present: Wellcome Trust Early Career Fellow (University of Glasgow) and Honorary Consultant Nephrologist (NHS Greater Glasgow and Clyde)
* 2025-present: Deputy Director of Research, School of Cardiovascular and Metabolic Health, University of Glasgow

**GMC registration** 2009-present:Registered with a licence to practice (GMC #7041214)

2022-present: Specialty register for Renal and General Internal Medicine

In my current employment, 80% of my time is dedicated to academic work: primarily research, with a small component for teaching and supporting professional activities. As Honorary Consultant Nephrologist (NHS Greater Glasgow and Clyde; 2022-present), I spend 20% of my time contributing to the west of Scotland nephrology service, providing care to outpatients and inpatients and contributing to the emergency rota.

## Education and qualifications

* 2022: Certificate of Completion of Training (CCT) – Nephrology and General Internal Medicine
* 2020: Doctor of Philosophy (PhD) – Medicine: University of Glasgow
* 2019: Specialty Certificate Examination (SCE) – Nephrology: Royal College of Physicians
* 2012: Member of the Royal College of Physicians (MRCP): Royal College of Physicians
* 2010: Master of Arts (MA; Cantab): University of Cambridge
* 2009: Bachelor of Medicine Bachelor of Surgery (MBChB): University of Edinburgh
* 2006: Bachelor of Arts (BA; Hons): University of Cambridge

## Employment history

* 2022-2024: Post-CCT Senior Clinical Research Fellow in Renal Medicine (University of Glasgow) and Honorary Consultant Nephrologist (NHS Greater Glasgow and Clyde)
* 2020-2022: Clinical Lecturer in Renal Medicine (University of Glasgow) and Honorary Specialty Registrar in Nephrology and General Internal Medicine – West of Scotland
* 2019-2020: Specialty Registrar in Nephrology and General Internal Medicine – West of Scotland
* 2016-2019: Out of programme research experience: PhD at the University of Glasgow
* 2013-2016: Specialty Registrar in Nephrology and General Internal Medicine – West of Scotland
* 2011-2013: Core Medical Training – South-East Scotland
* 2009-2011: Academic Foundation Training – South-East Scotland

**Grants and research funding**

**Personal fellowships** *– awarded to self*

* 2024-2029: Wellcome Trust Early Career Award (301005/Z/23/Z): £1,119,039. “Kidney function as a complicator of cancer treatment”
* 2020-2022: NHS Education for Scotland/Chief Scientist Office Postdoctoral Lectureship Scheme (PCL/20/10): salary + £20,000 consumables. “Defining the bi-directional relationship between cancer and kidney disease”
* 2017-2019: Kidney Research UK Training Fellowship (TF\_013\_20161125): £171,115. “Vitamin K in Transplanted kidney Organ Recipients: Investigating vEssel Stiffness (ViKTORIES)”
* 2016-2017: British Heart Foundation Centre of Research Excellence Award (RE/13/5/30177): salary + £30,000 consumables.

**Principal investigator project grants** - *awarded to self*

* 2024-2025: Karolinska Institutet Research Foundation Grants (2024-02610): SEK 282,800. “The role of kidney function in cancer treatment eligibility and clinical outcomes”.
* 2007-2012: 10 project/travel grants during undergraduate/early postgraduate career: total £11,115.

**Co-investigator project grants** - *awarded to collaborators*

* 2025: Chief Scientist Office Health Improvement, Protection and Services Research Grant (HIPS/24/31): £349,802. **“Scottish Cardiometabolic Assessment and Risk Determination: SCOTCARD”.**
* 2024-2026: International Society of Nephrology, Clinical Research Programme: USD 19,988. “Cystatin C in Africa: CKD screening, diagnosis, and predicting outcomes”.
* 2024-2025: Kidney Research UK Project Grant (RP\_015\_20221129): £80,869. “Kidney-related adverse events associated with intravitreal VEGF-inhibitor use: a national cohort Study”.
* 2022-2023: USyd-UofG Partnership Award: AUD 30,539. “Sex and Health; Evaluating diagnosis, Risk factOrs and Complications in chronic Kidney diSease (SHE-ROCKS)”.

## Selected professional activities

## International

* 2024-present: Elected Ordinary Member, European Renal Association Council
* 2023-2024: International Mentor for European Renal Association Young Nephrologists’ Platform
* 2023-present: Biomarkers/Formulas Editor, Nephrology Dialysis Transplantation
* 2019-present: Graphical Abstracts Editor, Nephrology Dialysis Transplantation

**Local**

* 2023-present: Patient and Public Involvement and Engagement (PPIE) steering committee, College of Medical and Veterinary Life Science, University of Glasgow
* 2021-present: Lead for West of Scotland Kidney Research PPIE Group

**Peer review including grants**

* Manuscript peer review for respected medical journals, including Nature Medicine, New England Journal of Medicine, The BMJ and The Lancet.
* Reviews of international and national project grants and personal fellowship on behalf of UK Research and Innovation: Medical Research Council, Barts Charity UK, Kidney Research UK, the Danish Heart Foundation.

**Selected international invited seminars and presentations**

* 2025: International Society of Nephrology Webinar: Innovative trial designs and generalizability in clinical research – “Generalizability and gender issues in clinical trials”
* 2025: European Renal Association Annual Congress (Vienna) - “State of the art and future directions for managing atherosclerotic vascular disease in CKD”
* 2025: European Renal Association Education meeting (Lisbon): “How to assess kidney function and diagnose CKD”
* 2024: International Society of Nephrology PARADIGM Consensus Meeting (Vancouver): “Reconsidering clinical trials based on single targets or thresholds: appreciating individual variability”
* 2024: European Renal Association Annual Congress (Stockholm): “The role of eGFR slope analyses in trials: an update”
* 2023: World Congress of Nephrology (Bangkok): Women in Nephrology “Rising Stars in Nephrology” session - “Cystatin C in Chronic Kidney Disease”
* 2023: European Society of Hypertension (Milan/Hybrid): “GFR, Cystatin C and Cardiovascular Disease in CKD”
* 2023: Pre-hypertension, Hypertension and Cardiometabolic Syndrome (Prague/Hybrid): “GFR, Cystatin C and Cardiovascular Disease in CKD”

**Prizes, honours and awards**

* 2024: Fellow of the European Renal Association
* 2022: Eberhard-Ritz Award, European Renal Association: Young Investigator Award for Clinical Science
* 2022: Raine Award, UK Kidney Association: for significant contribution to renal research by a researcher who has not reached consultant grade
* 2022: University of Glasgow “People Make Research: CAREERS” – recognized by University of Glasgow colleagues for making a positive difference to their career journey

## Relevant research skills and experience

**Trials**

* 2025-present: Steering Committee UK, IMPEDE-PKD trial (NCT04939935)
* 2024-present: Principal Investigator (Glasgow), SYNCHRONIZE-CVOT (Boehringer Ingelheim)
* 2019-present: UK Renal Trials Network member
* 2017-2019: Chief Investigator (ViKTORIES; ISRCTN22012044; funded Kidney Research UK). Published: **Lees JS** et al, Am J Transplant (2021); doi:10.1111/ajt.16566
* 2016-2019: Co-investigator (K4Kidneys; ISRCTN21444964; funded British Heart Foundation). Published: Witham MD, **Lees JS**, et al. J Am Soc Nephrol (2020); 31(10): 2434-2445

Current valid GCP certificate (2016, renewed 2018, 2021, 2023)

MRC Research, GDPR and Confidentiality (2020, renewed 2023)

**Publications and other academic outputs**

* **Publications:** 87 (31% first author; 25% corresponding author; 18% last author)
* **H-index:** Web of Science 20, Google Scholar 23.
* **ORCiD:** <https://orcid.org/0000-0001-6331-0178>
* **Highest Altmetrics scores:** 810\*\*\* (ref #25), 808\*\* (ref #22), 167\*(ref #13)

**Most significant publications – WHY? WHAT WAS MY CONTRIBUTION?**

**\*Lees JS**, Welsh CE, Celis-Morales C, et al. “Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease”. Nat Med (2019): 25; 1753-1760. Author correction: Nat Med (2020); 26(8): 1308.

Epi experience, major publication, important and highly-cited paper on cystatin C. Inspired further work by CKD prognosis consortium published in JAMA that was influential in the recent update to the international guidance on CKD diagnosis and management. Conducted on the side of PhD project.

**Lees JS**, Fu EL, Faucon A, et al. “Accuracy of glomerular filtration rate estimates among patients with cancer”. Br J Cancer (2025) [in press]

This is the first output from my Wellcome fellowship, significant as: i) the subject matter provides the rationale and pilot work for objective 3 in the current research application, and ii) it provides evidence that I have recently initiated and led a project collaborating with colleagues across specialties (epidemiology, nephrology, oncology) and across institutions (University of Glasgow, Tufts University, Karolinska Institutet) relevant to the delivery of the current research proposal.

**Lees JS**, Rankin AJ, Gillis KA, et al. “The ViKTORIES trial: a randomised, double-blind, placebo-controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients”. Am J Transplant (2021); 21(10): 3356-3368

Primary output from PhD. Evidence of ability to lead and complete a single centre trial.

**Primary research publications**

1. Dawson J, **Lees JS**, Chang T-P, Walters MR, Ali M, David SM, Diener H-C, Lees KR and for the GAIN and VISTA Investigators. “Association between disability measures and healthcare costs after initial treatment for acute stroke”. Stroke (2007); 38(6): 1893-1898
2. Quinn TJ, Dawson J, **Lees JS**, ChangTP, Walters MR, Lees KR, and for the GAIN and VISTA investigators. “Time spent at home post stroke: “Home-time” - a meaningful and robust outcome measure for stroke trials”. Stroke (2008); 39(1): 231-233
3. **Lees JS,** Mishra NK, Saini M, Lyden PD, Shuaib A. “Low body temperature does not significantly compromise therapeutic effect of alteplase”. Stroke (2011); 42(9): 2618-2621
4. **Lees JS,** Sena ES, Egan K, et al. “Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis”. Int J Stroke (2012); 7(7): 582-528
5. Antonic A, Sena ES, **Lees JS**, et al. “Stem cell transplantation in traumatic spinal cord injury: a systematic review and meta-analysis of animal studies.” PLoS Biol (2013); 11(12) e1001738
6. **Lees JS,** McQuarrie EP, Mordi N, et al. “Risk factors for bleeding complications after nephrologist-performed native renal biopsy”. Clin Kidney J (2017); 10(4): 573-577
7. Stoumpos S, **Lees J**, Welsh P, et al. “The utility of anti-Mullerian hormone in women with chronic kidney disease, on haemodialysis and after kidney transplantation”. Reprod Biomed Online (2018); 36(2): 219-226
8. Gillis KA, **Lees JS**, Ralston MR, et al. “Interaction between socioeconomic deprivation and likelihood of pre-emptive transplantation: influence of competing risks and referral characteristics – a retrospective study”. Transpl Int (2018); https://doi.org/10.1111/tri.13336
9. **Lees JS,** Findlay M, Mark PB, Geddes CC. “The impact of coronary angiography on renal transplant function”. QJM (2018); 112(1): 23-27
10. Elyan BMP, **Lees JS,** Gillis KA, et al. “Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases”. BMC Nephrol (2019); 20(1): 237
11. Grant CH, Gillis KA, **Lees JS,** et al. “Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis”. QJM (2019); <https://doi.org/10.1093/qjmed/hcz166>
12. **Lees JS,** Chapman FA, Witham MD, Jardine AG, Mark PB. “Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis”. Heart (2019); 105(12): 938-945
13. **\*Lees JS**, Welsh CE, Celis-Morales C, et al. “Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease”. Nat Med (2019): 25; 1753-1760. Author correction: Nat Med (2020); 26(8): 1308.
14. **Lees JS**, Mangion K, Rutherford E, et al. “Vitamin K for kidney transplant organ recipients: investigating vessel stiffness (ViKTORIES): study rationale and protocol of a randomised controlled trial”. Open Heart (2020); 7: e001070. https://doi.org/10.1136/openhrt-2019-001070
15. Witham MD, **Lees JS**, White M, et al. “Vitamin K supplementation to improve vascular stiffness in chronic kidney disease - the K4Kidneys randomised controlled trial”. J Am Soc Nephrol (2020); 31(10): 2434-2445
16. Rankin AJ, Zhu L, Mangion K, et al **(Lees JS, middle author)**. “Global longitudinal strain by feature-tracking cardiovascular magnetic resonance imaging predicts mortality in patients with end-stage kidney disease”. Clin Kidney J (2021); 14(10): 2187-2196
17. O’Sullivan E, **Lees JS**, Howie KL, et al. “Prolonged SARS-CoV-2 viral shedding in patients with chronic kidney disease”. Nephrology (2021); 26 (4): 328.322
18. **Lees JS**, Rankin AJ, Gillis KA, et al. “The ViKTORIES trial: a randomised, double-blind, placebo-controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients”. Am J Transplant (2021); 21(10): 3356-3368
19. Sullivan M, Jani B, **Lees JS**, et al. “Multimorbidity and the risk of major adverse kidney events: findings from the UK Biobank cohort”. Clin Kidney J (2021); 14(11): 2409-2419
20. Li KK, Woo YM, Stirrup O, et al **(Lees JS, middle author)**. “Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units – a high risk community-hospital interface.” J Infection (2021); 83(1): 96-103
21. Edy E, Rankin AJ, **Lees JS**, et al. “Cardiovascular MRI for the detection of thoracic aorta calcification in patients with end-stage renal disease”. J Cardiovasc Magn Reson (2021); 23(1): 85
22. **\*\*Lees JS,** Ho F, Parra-Soto S, et al. “Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study”. EClinicalMedicine (2021); 38: 101030
23. Sullivan MK, **Lees JS,** Drake TM, et al. “Acute kidney injury in patients hospitalised with COVID-19 from the ISARIOC WHO CCP-UK Study”. Nephrol Dial Transplant (2021) [online ahead of print]
24. Rankin AJ, Mangion K, **Lees JS,** et al. “Myocardial changes on 3T cardiovascular magnetic resonance imaging in response to haemodialysis with fluid removal”. J Cardiovasc Magn Reson (2021); 23(1): 125
25. **\*\*\***Sullivan MK, Jani B, Rutherford E, et al. (**Lees JS, senior author).** “Potential impact of NICE guidelines on referrals from primary care to nephrology”. Br J Gen Practice (2022); 73(727): e141-147
26. Morrow AJ, Sykes R, McIntosh A, et al **(consortium member).** “A multi-system cardio-renal investigation of post-COVID-19 illness. Nat Med (2022); 28(6): 1303-1313.
27. Mayne KJ, Shemilt R, Keane DF, **Lees JS (joint senior author)**, Mark PB, Herrington WG. “Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review”. J Card Fail (2022) 28(11):1628-1641. https://doi.org/10.1016/j.cardfail.2022.08.005
28. **Lees JS**, Hanlon P, Butterly E, et al. “The impact of age, sex and morbidity count on trial attrition: a meta-analysis of individual participant-level data from phase 3/4 industry-funded clinical trials”. BMJ Medicine (2022) 1(1): e000217
29. **Lees JS**, Rutherford E, Stevens KI, et al. “Assessment of Cystatin C for risk stratification in adults with chronic kidney disease”. JAMA Netw Open (2022); 5(1): e2238300
30. Mayne KJ, **Lees JS**, Rutherford E et al. “Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort.” Clin Kidney J (2022) 16(3): 512-520
31. Mayne KJ, Shemilt R, Kean DF, et al **(Lees JS**, **joint senior author)**. “Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review”. J Card Fail (2022) 29(11): 1628-1641
32. Lithgow H, Johnston L, Ho FK et al **(Lees JS, middle author).** “Protocol for a randomised controlled trial to investigate the effects of vitamin K2 on recovery from muscle damaging resistance exercise in young and older adults – the TAKEOVER study.” Trials (2022) 23(1): 1026
33. Chen DC, **Lees JS**, Lu K et al. “Differential associations of cystatin C versus creatinine based kidney function with risks of cardiovascular event and mortality among South Asian individuals in the UK Biobank”. J Am Heart Assoc (2022) 12(3): e027079
34. **Lees JS**, De La Mata N, Sullivan MK et al. “Sex differences in associations between creatinine and cystatin C-based kidney function measures with stroke and major bleeding”. European Stroke Journal (2023); 8(3): 756-768
35. Mangion K, Morrow AJ, Sykes R et al **(Lees JS, consortium member).** “Post-COVID-19 illness and associations with sex and gender”. BMA Cardiovasc Disord (2023); 23(1): 389
36. McGovern D, **Lees JS,** Traynor JP et al. “Outcome in ANCA-associated vasculitis in Scotland: validation of the renal risk score in a complete national cohort”. Kidney International Reports (2023); 8(8): 1648-1656
37. Grams ME, Coresh J, Matsushita K et al **(Lees JS, middle author).** “Estimated glomerular filtration rate, albuminuria and adverse outcomes: an individual participant meta-analysis”. Journal of the American Medical Association (2023) 330(13): 1266-1277.
38. Jani BD, Sullivan MK, Hanlon P et al **(Lees JS, middle author)**. “Personalised Lung Cancer Risk Stratification and Lung Cancer Screening: Do General Practice Electronic Medical Records have a Role?”. British Journal of Cancer (2023) 129(12): 1968-1977
39. **Lees JS**, Dobbin SJH, Elyan BMP, et al. “A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.” Nephrol Dial Transplant (2023) 38(7): 1666-1681
40. Elyan BMP, Rankin S, Jones R, Lang NN, Mark PB, **Lees JS (senior author)**. “Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review”. Kidney Medicine (2023) 5(7): 100672
41. Rankin S, Elyan BMP, Jones RC et al **(Lees JS, middle author)**. “Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitor trials”. JACC Cardio-Oncology 2024: https://doi.org/[10.1016/j.jaccao.2023.12.010](https://doi.org/10.1016/j.jaccao.2023.12.010)
42. Mayne KJ, Staplin N, Keane D et al (**Lees JS, middle author**). “Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease”. J Am Soc Nephrol (2024) 35(2):202-215. <https://doi.org/10.1681/ASN.0000000000000271>
43. Bate S, McGovern D, Costigliolo F et al (**Lees JS, middle author**). “The Improved Kidney Risk Score in ANCA Vasculitis for Clinical Practice and Trials”. J Am Soc Nephrol (2024) 35(3):335-346. <https://doi.org/10.1681/ASN.0000000000000274>
44. Shemilt R, Sullivan MK, Hanlon P et al **(Lees JS, senior author).** “Sex differences in the diagnosis of advanced cancer and subsequent outcome across the range of eGFR”. Nephrol Dial Transplant (2024) 39(11): 1799-1808; <https://doi.org/10.1093/ndt/gfae059>
45. Chen DC, Lu K, Scherzer R, **Lees JS** et al. “Cystatin C and Creatinine-based estimated GFR differences: prevalence and predictors in the UK Biobank”. Kidney Medicine (2024): 6(4); 100796s
46. **Lees JS**, Crowther J, Hanlon P et al. “Participant characteristics and exclusion from trials: a meta-analysis of individual participant-level data from phase 3/4 industry-funded trials in chronic medical conditions”. BMJ Medicine (2024) 3(1): e000732; <https://doi.org/10.1136/bmjmed-2023-000732>
47. Sullivan MK, **Lees JS**, Rosales BM et al. “Sex and the relationship between cardiometabolic risk factors and estimated GFR decline: a population-based cohort study”. Am J Kidney Dis (2024); <https://doi.org/10.1053/j.ajkd.2024.05.007>
48. Liu Q, Celis-Morales C, **Lees JS** et al. “Change in physical activity and its association with decline in kidney function: A UK Biobank-based cohort study”. J Cachexia Sarcopenia Muscle (2024); 15(5): 2046-2055. <https://doi.org/10.1002/jcsm.13551>
49. Elyan BMP, Sullivan MK, Hedley J et al (**Lees JS, senior author**). “The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis.” BJC Reports (2024); <https://doi.org/10.1038/s44276-024-00081-7>
50. Marshall W, Curran G, Traynor JP et al (**Lees JS, senior author**). “Sodium zirconium cyclosilicate treatment and rates of emergency interventions for hyperkalaemia: a propensity-score weighted case-control study”. Clin Kidney J (2024): [https://doi.org/10.1093/ckj/sfae313](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1093%2Fckj%2Fsfae313&data=05%7C02%7CJennifer.Lees%40glasgow.ac.uk%7C09c5b8d8ed1c4efce6a908dd46e02266%7C6e725c29763a4f5081f22e254f0133c8%7C1%7C0%7C638744650648541046%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=nfw4PzkPchbsnYeM5T2j%2B%2FV7Z5fuemYOL%2BMamD3B1n0%3D&reserved=0)
51. Liu Q, Celis-Morales C, **Lees JS** et al. “Effect of exercise on kidney-relevant biomarkers in the general population: A systematic review and meta-analysis”. BMJ Open (2024): https://doi.org/10.1136/bmjopen-2024-093017
52. Liu Q, Welsh P, Celis-Morales C et al (**Lees JS, middle author**). “Discordance between Cystatin C-based and Creatinine-based estimated glomerular filtration rate and health outcomes in adults: a systematic review and meta-analysis”. Clin Kidney J (2025): 18(3); [https://doi.org/10.1093/ckj/sfaf003](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1093%2Fckj%2Fsfaf003&data=05%7C02%7CJennifer.Lees%40glasgow.ac.uk%7C09c5b8d8ed1c4efce6a908dd46e02266%7C6e725c29763a4f5081f22e254f0133c8%7C1%7C0%7C638744650648493272%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=0kWs33Igs%2FFa8Bp%2FsRqWUByIkD1KvcGANo9a%2BLPwKSs%3D&reserved=0)
53. Rochmawati I, Deo S, **Lees JS** et al. “Adding traditional and emerging biomarkers for risk assessment in secondary prevention: A prospective cohort study of 20,656 patients with cardiovascular disease”. European Journal of Preventative Cardiology (2025): <https://doi.org/10.1093/eurjpc/zwae352>
54. Ho F, Mark PB, **Lees JS** et al. “A proteomics-based approach for prediction of different cardiovascular diseases and dementia”. Circulation (2025); 151(5): 277-287. <https://doi.org/10.1161/CIRCULATIONAHA.124.070454>
55. Sykes R, Morrow AJ, Mangion K et al (**Lees JS, consortium author**). “Radiological abnormalities persist following COVID-19 and correlate with impaired health-related quality of life: a prospective study of hospitalised patients”. BMJ Open Respir Res (2025); 12(1): e001985. <https://doi.org/10.1136/bmjresp-2023-001985>
56. Elyan BMP, Tan B, Lambourg E, et al (**Lees JS, middle author**). “Incidence of cancer in people with CKD not requiring kidney replacement therapy: A systematic review and meta-analysis”. Clin Kidney J (2025): <https://doi.org/10.1093/ckj/sfaf084>
57. McChrystal R, **Lees JS**, Gillies K, et al. “Participant and trial characteristics reported in predictive analyses of trial attrition: An umbrella review of systematic reviews of randomised controlled trials across multiple conditions”. Trials (2025); <https://doi.org/10.1186/s13063-025-08794-x>
58. Liu Q, Celis-Morales C, **Lees JS**, et al. “Discordance between cystatin C-based and creatinine-based estimated glomerular filtration rate and mortality in general population: evidence from the UK Biobank”. Clin Chemistry (2025): <https://doi.org/10.1093/clinchem/hvaf063>
59. Mok Y, Surapaneni A, Sang Y et al (**Lees JS, senior author**). “Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis”. Br J Cancer (2025) [in press]
60. Ishigami J, Surapaneni A, Matsushita K, et al (**Lees JS, middle author**). “Estimated glomerular filtration rate, albuminuria, and risk of infection: a collaborative meta-analysis of individual participant data”. EClinicalMedicine (2025) [in press]
61. Walker HJ, Carrero JJ, Sullivan MK et al (**Lees JS, middle author**). “Frailty in Adults with Chronic Kidney Disease and Validation of the Kidney Failure Risk Equation in Frailty Sub-Groups”. Clin J Am Soc Nephrol (2025): [https://doi.org/10.2215/CJN.0000000739](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.2215%2FCJN.0000000739&data=05%7C02%7CJennifer.Lees%40glasgow.ac.uk%7C5f85d68c725e46126c3008ddd6661cc1%7C6e725c29763a4f5081f22e254f0133c8%7C1%7C0%7C638902456239133499%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NgrWoZuqwzSl9X4oJ8mGqN6Tan2eccSSJNPyBFO%2BKgA%3D&reserved=0)
62. Mayne KJ, Walker H, Elyan BMP et al (**Lees JS, senior author**). “Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study”. Eur J Prevent Cardiol (2025) [in press]
63. **Lees JS**, Fu EL, Faucon A, et al. “Accuracy of glomerular filtration rate estimates among patients with cancer”. Br J Cancer (2025) [in press]
64. Estrella ME, Ballew SH, Sang Y et al (**Lees JS, middle author**). “Discordance in creatinine based eGFR and cystatin C based eGFR and clinical outcomes A meta-analysis”. JAMA (2025) [in press]
65. McChrystal R, Hanlon P, **Lees JS** et al. “Modelling rates of trial attrition: An analysis of individual participant data from 90 randomised controlled trials of pharmacological interventions for multiple conditions.” J Clin Epidemiol (2025) [in press]
66. Levin A, Jaure A, Little DJ et al (**Lees JS, middle author**). “Changing paradigms of studies in kidney disease”. Kidney Int (2025) [in press]
67. Mark PB, Stafford L, Grams ME et al (**Lees JS, joint senior author**). “Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis of the Global Burden of Disease Study 2023”. The Lancet (2025) [in press]

**Reviews**

1. **Lees JS,** Mark PB, Jardine AG. “Cardiovascular complications of chronic kidney disease.” Medicine (2015); 43 (8): 469-473.
2. **Lees JS,** Mark PB, Witham MD. “Vitamin K and vascular calcification” Curr Opin Nephrol Hypertens (2021); 30(4): 430-436
3. **Lees JS,** Elyan BMP, Herrmann SM, et al. “The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes”. Nephrol Dial Transplant (2023) 38(5): 1071-1079
4. Mayne KJ, **Lees JS**, Mark PB. “Cardiovascular complications of chronic kidney disease.” Medicine (2022).
5. Mayne KJ, **Lees JS**, Herrington WG. “Bioimpedance in CKD: an untapped resource?”. Nephrol Dial Transplant (2023) 38(3): 583-585
6. Grant CH, Salim E, **Lees JS,** Stevens KI. Deprivation and chronic kidney disease: a review of the evidence. Clin Kidney J (2023) 16(7): 1081-1091
7. Mayne KJ, Sullivan MK, **Lees JS (senior author). “**Sex and gender differences in the management of chronic kidney disease and hypertension”. Journal of Human Hypertension (2023) 37(8): 649-653
8. **Lees JS,** Fabian J and Shlipak MJ. “Cystatin C should be routinely available for estimating kidney function”. Curr Opin Nephrol Hypertension (2024): 33(3):337-343.
9. Mayne KJ, Hanlon P, **Lees JS (senior author)**. “Detecting and Managing the Patient with CKD in Primary Care: A Review of the Latest Guidelines”. Diabetes Obes Metab 2024: <http://dx.doi.org/10.1111/dom.15625>.

**Editorial/commentary**

1. **Lees JS**,McQuarrie EP,Mackinnon B.“Renal biopsy: it is time for pragmatism and consensus”.Clin Kidney J (2018); 11(5): 605-609
2. **Lees JS**, Mark PB. “Cystatin C to predict renal disease and cardiovascular risk”. Nephrol Dial Transplant (2020); 36 (1): 39-41
3. **Lees JS** and Mark PB**.** “Fruit for thought: lifestyle interventions to reduce the risk of future chronic kidney disease”. Nephrol Dial Transplant (2021); 36(6): 963-965
4. **Lees JS** and Mark PB. “Insights into vitamin K metabolism in chronic kidney disease: more complicated than kale deficiency”. Kidney Int (2022); 101(2): 216-219
5. **Lees JS** and Shlipak MG. “Age-adapted eGFR thresholds underestimate risks beyond kidney failure associated with CKD in older populations”. J Am Geriat Soc (2022) 70(12): 3660-3664
6. Stevens KI, Graham-Brown M, **Lees JS (senior author)**. “Let’s get physical: considering and overcoming the barriers to physical activity in CKD”. Nephrol Dial Transplant (2022) 38(6): 1405-1407
7. Stevens KI and **Lees JS (senior author).** “Measure and risk: Cystatin C, creatinine and controversy in CKD”. Nephrol Dial Transplant (2023) 38(8): 1785-1788
8. Radley A, **Lees JS**, Stevens KI. “Cardiovascular disease in older women with CKD”. Clin Kidney J (2023); 16(12): 2304-2308
9. **Lees JS** and Mark PB. “GFR slope as a surrogate marker for future kidney failure”. Nature Reviews Nephrology (2023) 19(10): 625-626

**Case reports**

1. **Lees JS**, Church N, Langdale-Brown B, Bellamy C, Gibson P, Watson S. “IgG4-related disease: a novel, important but easily missed condition.” J R Coll Physicians Edinb. (2013); 43(2): 126-33.
2. Groome C, Doak A, Stirling C, **Lees JS (senior author)**. “Under pressure”. Hypertension Journal (2023) 7(2): 99-102

## Book chapters

* **Lees JS**, Jardine AG. “Chapter 30: Cardiovascular Disease in Renal Transplantation”, Kidney Transplantation – Principles and Practice 8th Edition, Elsevier [2019]
* Shemilt R, **Lees JS**, Mark PB. “Chapter 30: Cardiovascular Disease in Renal Transplantation”, Kidney Transplantation – Principles and Practice 9th Edition, Elsevier [2024]

## Reports

Contributing author. “Time To Act: A New Review of Kidney Health Inequalities”. Kidney Research UK (2024).